Plain-English translation of NCT06151080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for a rare form of lymphoma where two types of cancer cells—diffuse large B-cell lymphoma and follicular lymphoma—are found together in the same patient. The study combines a medication called lenalidomide with a standard four-drug chemotherapy regimen (called G-CHOP) to see if this combination works better than chemotherapy alone. Researchers want to measure how many patients respond completely to the treatment and how long they stay in remission.
When two types of lymphoma occur together, standard treatments don't always work as well as doctors hope. This trial exists to find out whether adding lenalidomide to the standard chemotherapy approach can improve survival and help more patients achieve long-term remission.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the medication lenalidomide combined with four chemotherapy drugs (G-CHOP) over a planned course of treatment. You'll have regular clinic visits for check-ups, blood tests, and imaging scans to see how well the treatment is working and to watch for side effects. The study involves close monitoring of your health throughout treatment and follow-up visits afterward to track how long your remission lasts.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Collaborators
The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University
Enrollment target
~38 participants
Started
November 2023
Primary completion
August 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bing Xu, PhD
The First Aiffiliated hosptical of xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.